BlueWhale Bio Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 29

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $5M

  • Investors
  • 6

BlueWhale Bio General Information

Description

Developer of a cell-based therapeutic platform designed for gene therapy manufacturing. The company's platform utilizes cell-derived nanoparticles that mimic the natural immune synapse to deliver physiological activation cues, membrane-bound signals, and cytokines, enabling cell therapy developers to achieve faster manufacturing timelines and improved cell persistence.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2929 Arch Street
  • Philadelphia, PA 19104
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 2929 Arch Street
  • Philadelphia, PA 19104
  • United States

BlueWhale Bio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BlueWhale Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series A) 30-Jun-2026 $5M Completed Clinical Trials - General
2. Seed Round 01-Aug-2023 Completed Clinical Trials - General
1. Accelerator/Incubator Completed Clinical Trials - General
To view BlueWhale Bio’s complete valuation and funding history, request access »

BlueWhale Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Seed
To view BlueWhale Bio’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

BlueWhale Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a cell-based therapeutic platform designed for gene therapy manufacturing. The company's platform utilizes
Drug Discovery
Philadelphia, PA
29 As of 2026

Mississauga, Canada
 

San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BlueWhale Bio Competitors (68)

One of BlueWhale Bio’s 68 competitors is Sernova Biotherapeutics, a Corporation company based in Mississauga, Canada.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sernova Biotherapeutics Corporation Mississauga, Canada
Verge Labs Venture Capital-Backed San Francisco, CA
AltPep Venture Capital-Backed Seattle, WA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Alzheon Venture Capital-Backed Framingham, MA
You’re viewing 5 of 68 competitors. Get the full list »

BlueWhale Bio Patents

BlueWhale Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026076459-A1 Compositions and methods related to populations of cell-derived nanoparticles (cdnps) Pending 06-Oct-2024

BlueWhale Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BlueWhale Bio Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Ben Franklin Technology Partners of Southeastern Pennsylvania Accelerator/Incubator Minority
Danaher Ventures Corporate Venture Capital Minority
Hillhouse Investment Group PE/Buyout Minority
Marshall Wace Hedge Fund Minority
Novalis LifeSciences Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

BlueWhale Bio FAQs

  • When was BlueWhale Bio founded?

    BlueWhale Bio was founded in 2022.

  • Where is BlueWhale Bio headquartered?

    BlueWhale Bio is headquartered in Philadelphia, PA.

  • What is the size of BlueWhale Bio?

    BlueWhale Bio has 29 total employees.

  • What industry is BlueWhale Bio in?

    BlueWhale Bio’s primary industry is Drug Discovery.

  • Is BlueWhale Bio a private or public company?

    BlueWhale Bio is a Private company.

  • What is the current valuation of BlueWhale Bio?

    The current valuation of BlueWhale Bio is .

  • What is BlueWhale Bio’s current revenue?

    The current revenue for BlueWhale Bio is .

  • How much funding has BlueWhale Bio raised over time?

    BlueWhale Bio has raised $23M.

  • Who are BlueWhale Bio’s investors?

    Ben Franklin Technology Partners of Southeastern Pennsylvania, Danaher Ventures, Hillhouse Investment Group, Marshall Wace, and Novalis LifeSciences are 5 of 6 investors who have invested in BlueWhale Bio.

  • Who are BlueWhale Bio’s competitors?

    Sernova Biotherapeutics, Verge Labs, AltPep, Adaptimmune Therapeutics, and Alzheon are some of the 68 competitors of BlueWhale Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process